Why Sarepta Therapeutics Stock Is Booming Today

Sarepta Therapeutics SRPT shares are trading higher this Wednesday after the company reported better-than-expected fourth-quarter results.

What Happened: On Tuesday, Sarepta Therapeutics announced its results for the fourth quarter and full-year 2022 ended Dec. 31, 2022.

The Details: Sarepta announced quarterly earnings (losses) of $(0.53) per share compared to the analyst consensus estimate of $(1.53) per share, representing a positive earnings surprise of 60.7%. The company announced quarterly sales of $258.43 million compared to the analyst estimate of $248.43 million, representing a positive earnings surprise of 4.1%.

Sarepta Therapeutics reported yearly earnings of $(3.06) compared to earnings of $(3.80) per share last year. The company announced yearly total sales of $933.0 million, compared to $701.9 million in 2021.

Sarepta achieved these stellar results by prioritizing our patients and without taking a single price increase in over 6 years," said Doug Ingram, Sarepta's president and chief executive officer.

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. It holds leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophy (LGMDs), and the company currently has more than 40 programs in various stages of development.

According to data from Benzinga Pro, Sarepta Therapeutics shares were up 18.0%, trading at $144.17 at the time of publication. The stock has a 52-week high of $134.08 and a 52-week low of $61.28.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!